A Microfluidic Chemotaxis High Throughput System

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43HL088785-01
Agency Tracking Number: HL088785
Amount: $301,884.00
Phase: Phase I
Program: SBIR
Awards Year: 2007
Solicitation Year: 2007
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
5500 Nobel Drive, Suite 250, MADISON, WI, 53711
DUNS: 119165251
HUBZone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: Y
Principal Investigator
 (608) 695-5812
Business Contact
Phone: (608) 227-4501
Research Institution
DESCRIPTION (provided by applicant): Neutrophil recruitment is a central component of inflammation, and there is intense focus on inhibiting the process both for chronic inflammatory disorders and for conditions where inflammation plays a contributory role, such as atherosclerosis. Chemotaxis - the movement of cells aligned with a chemical gradient - is the fundamental process underlying neutrophil recruitment. Despite its importance, screening tools for high throughput analysis of neutrophil recruitment are limited and there are none that allow quantitative measurement of cell chemotaxis in a defined gradient. Accordingly, the goal of this Phase I proposal is to develop a novel microfluidics device - called the Microfluidic Chemotaxis High Throughput System fFCXHTS (Fig. 1) - for high throughput assays of neutrophil chemotaxis in a defined, stable chemical gradient. The project is a collaboration between Salus Discovery, a developer of microfluidic technology, and Dr. Anna Huttenlocher at the University of Wisconsin - Madison, who brings extensive experience in the molecular analysis of leukocyte chemotaxis. In preliminary studies, Dr. David Beebe - a scientific founder of Salus Discovery - and Dr. Huttenlocher developed the basic design for the static gradient chamber of the fFCXHTS and validated a single-assay prototype device fabricated from elastomeric polymer. In Phase I, we will show feasibility for fabrication of a commercial fFCXHTS device. The static gradient chamber will be incorporated into an array format, methods for fabrication from polystyrene will be developed, and the resulting fFCXHTS will be validated for identification of compounds that inhibit neutrophil migration. The migration of cells from the bloodstream to sites of injury is one of the fundamental processes underlying chronic inflammatory disorders such as arthritis and inflammatory bowel disease. Responding cells migrate toward higher concentrations of signaling molecules that are released at the injury site. To enable the discovery of drugs to block this process, we are developing plastic devices for high throughput cell migration assays in defined chemical gradients.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government